Patient and tumor characteristics | Entire cohort (N = 59) | aPatients included in theefficacy analysis (N = 55) |
---|---|---|
Age at diagnosis (years) – median (range) | 55 (33–75) | 55 (33–75) |
Male gender | 46 (78%) | 43 (78%) |
Prior nephrectomy | 56 (95%) | 52 (95%) |
Prior IO-VEGF combination by category | ||
 IO-Bev | 35 (59%) | 33 (60%) |
 IO-TKI | 24 (41%) | 22 (40%) |
Prior IO-VEGF combinations by regimen | ||
 Atezolizumab and bevacizumab | 34 (58%) | 32 (58%) |
 Avelumab and axitinib | 12 (20%) | 11 (20%) |
 Pembrolizumab and lenvatinib | 8 (14%) | 7 (13%) |
 Pembrolizumab and pazopanib | 2 (3%) | 2 (3%) |
 Pembrolizumab and axitinib | 1 (2%) | 1 (2%) |
 Nivolumab and sunitinib | 1 (2%) | 1 (2%) |
 Nivolumab and bevacizumab | 1 (2%) | 1 (2%) |
Reason for discontinuation of IO-VEGF | ||
 Progression of disease | 55 (93%) | 51 (93%) |
 Toxicity | 3 (5%) | 3 (5%) |
 Other | 1 (2%) | 1 (2%) |
Time from discontinuation of IO-VEGF to start of the next line therapy (days) - median (range) | 28 (3–574) | 30 (3–615) |
IMDC risk at the start of next line of therapy | ||
 Favorable | 13 (22%) | 11 (20%) |
 Intermediate | 35 (59%) | 33 (60%) |
 Poor | 11 (19%) | 11 (20%) |
Post IO-VEGF next line of therapy | ||
 Cabozantinib | 22 (37%) | 22 (40%) |
 Axitinib | 18 (31%) | 18 (33%) |
 Pazopanib | 4 (7%) | 4 (7%) |
 Lenvatinib and everolimus | 4 (7%) | 4 (7%) |
 mTOR inhibitor monotherapy | 3 (5%) | 3 (5%) |
 Axitinib and dalantercept (Clinical trial) | 2 (3%) | 2 (4%) |
 Sunitinib | 1 (2%) | 1 (2%) |
 Sorafenib | 1 (2%) | 1 (2%) |
 Unreported clinical trials | 4 (7%) | – |
Number of therapy line post IO-VEGF | ||
 Second | 42 (71%) | 39 (71%) |
 Third | 17 (29%) | 16 (29%) |